Healthcare shares are flat in pre-market trade. Shares of Clovis
Oncology Inc. (
) are down 1.6% at $58.00 in pre-market trade as the company
announces the pricing of an underwritten public offering of two
million shares of its common stock at a price to the public of
$57.50 per share.
And, the Medicines Company (
) said it has acquired Rempex Pharmaceuticals, Inc., adding a range
of antibiotics to treat drug resistant gram-negative bacteria to
its infectious diseases portfolio.
The company will pay $140 million upfront, with a further $214
million in milestone payments and commercial milestone payments of
Finally, Ambit Biosciences (
) is down nearly 34% at $8.50 a share after saying it does not plan
on submitting a new drug application for accelerated approval of it
quizartinib drug candidate based on the Phase II and Phase IIb
clinical testing of the prospective treatment for acute myeloid
Following discussions with the U.S. Food and Drug
Administration, AMBI said it plans to move forward with Phase III
testing of quizartinib in leukemia patients who have relapsed or
refractory to prior treatments.